RxDoctor Payments Data

Trevor Batty, DO

Dermatology · Chubbuck, IDNPI 1558756106

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.8% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 33.0% of the total.

$4,206in general payments, 2019–2025

Across 286 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$753
  • Johnson & Johnson$474
  • Regeneron Healthcare Solutions, Inc.$235
  • Lilly USA, LLC$208
  • LEO Pharma Inc.$201
  • plus $949 from 20 others

What the payments were for

  • Food & beverage$3,90293%
  • Education$3047%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,206 in reported general payments places this provider in the 75th percentile of 52 dermatology providers in Idaho.

See all dermatology providers in Idaho

Medicare billing

Part B allowed, 2024
$337,102
Medicare patients
1,165
Services billed
10,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$217,806
Bimzelx AutoinjectorBimekizumab-Bkzx12$174,117
Cosentyx Sensoready (2 Pens)Secukinumab11$78,646
Dupixent PenDupilumab19$69,100
SotyktuDeucravacitinib11$64,090
Fluorouracil59$6,854
Clobetasol Propionate128$4,408
Metronidazole68$4,034
Ketoconazole189$3,010
Fluocinonide55$2,743
Imiquimod57$2,371
Clindamycin Phosphate47$2,282
Triamcinolone Acetonide207$2,254
Tacrolimus12$1,760
Doxycycline Hyclate40$966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$86$64,09011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 52 dermatology providers in Idaho.

Other dermatology in Chubbuck

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →